Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Mechanism of cytochrome P450-3A inhibition by ketoconazole.

Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL.

J Pharm Pharmacol. 2011 Feb;63(2):214-21. doi: 10.1111/j.2042-7158.2010.01202.x.

PMID:
21235585
3.

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ.

Clin Pharmacol Ther. 1999 Nov;66(5):461-71.

PMID:
10579473
4.

Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.

Perloff MD, von Moltke LL, Cotreau MM, Greenblatt DJ.

Biochem Pharmacol. 1999 Jun 1;57(11):1227-32.

PMID:
10230766
5.

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL.

Xenobiotica. 2010 Oct;40(10):713-20. doi: 10.3109/00498254.2010.506224. Review.

PMID:
20712450
6.
7.
8.

Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.

von Moltke LL, Durol AL, Duan SX, Greenblatt DJ.

Eur J Clin Pharmacol. 2000 Jun;56(3):259-61.

PMID:
10952482
9.

Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.

Patki KC, Greenblatt DJ, von Moltke LL.

J Pharm Pharmacol. 2004 Aug;56(8):963-6.

PMID:
15285839
10.
11.

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.

Ayan-Oshodi MA, Willis BA, Annes WF, Lowe SL, Friedrich S, de la Peña A, Zhang W, Brown T, Wise SD, Hall SD.

Drug Metab Dispos. 2012 Oct;40(10):1945-52. doi: 10.1124/dmd.112.046060. Epub 2012 Jul 12.

12.

Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.

Li X, Song X, Kamenecka TM, Cameron MD.

Drug Metab Dispos. 2012 Sep;40(9):1803-9. doi: 10.1124/dmd.112.046144. Epub 2012 Jun 13.

13.
14.
15.

Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.

Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ.

J Pharmacol Exp Ther. 2000 Feb;292(2):618-28.

16.

Differential effect of Shenmai injection, a herbal preparation, on the cytochrome P450 3A-mediated 1'-hydroxylation and 4-hydroxylation of midazolam.

Xia C, Sun J, Wang G, Shang L, Zhang X, Zhang R, Wang X, Hao H, Xie L.

Chem Biol Interact. 2009 Aug 14;180(3):440-8.

PMID:
19557931
17.

Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.

Martínez C, García-Martín E, Pizarro RM, García-Gamito FJ, Agúndez JA.

Br J Cancer. 2002 Sep 9;87(6):681-6.

18.

Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.

Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, Yamamoto K.

Drug Metab Dispos. 2008 Nov;36(11):2287-91. doi: 10.1124/dmd.108.021816. Epub 2008 Jul 31.

19.

Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.

Zhuang X, Zhang T, Yue S, Wang J, Luo H, Zhang Y, Li Z, Che J, Yang H, Li H, Zhu M, Lu C.

Biochem Pharmacol. 2016 Dec 1;121:67-77. doi: 10.1016/j.bcp.2016.09.012. Epub 2016 Sep 22.

PMID:
27666601
20.

[Effect of ketoconazole on the activity of CYP4503A4 and CYP450 1A2 of hepatic microsomes in healthy adults].

Yang GZ, Yuan Y, Zhou QX, Yang JQ, Liu YJ.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1634-5, 1639. Chinese.

PMID:
18819885

Supplemental Content

Support Center